These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35331501)

  • 41. Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials.
    Liu Y; Cao Y; Zhang S; Zhang W; Zhang B; Tang Q; Li Z; Wu J
    Climacteric; 2018 Apr; 21(2):189-195. PubMed ID: 29424257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
    Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Greater Gains in Spine and Hip Strength for Romosozumab Compared With Teriparatide in Postmenopausal Women With Low Bone Mass.
    Keaveny TM; Crittenden DB; Bolognese MA; Genant HK; Engelke K; Oliveri B; Brown JP; Langdahl BL; Yan C; Grauer A; Libanati C
    J Bone Miner Res; 2017 Sep; 32(9):1956-1962. PubMed ID: 28543940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and safety of vitamin D in relation to bone health.
    Cranney A; Horsley T; O'Donnell S; Weiler H; Puil L; Ooi D; Atkinson S; Ward L; Moher D; Hanley D; Fang M; Yazdi F; Garritty C; Sampson M; Barrowman N; Tsertsvadze A; Mamaladze V
    Evid Rep Technol Assess (Full Rep); 2007 Aug; (158):1-235. PubMed ID: 18088161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Skeletal responses to romosozumab after 12 months of denosumab.
    McClung MR; Bolognese MA; Brown JP; Reginster JY; Langdahl BL; Shi Y; Timoshanko J; Libanati C; Chines A; Oates MK
    JBMR Plus; 2021 Jul; 5(7):e10512. PubMed ID: 34258507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study.
    Inose H; Kato T; Tomizawa S; Ariga A; Motoyoshi T; Fukushima K; Takahashi K; Yoshii T; Okawa A
    Bone Rep; 2022 Dec; 17():101635. PubMed ID: 36389625
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
    Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
    Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation.
    Jiang Y; Tang H; Ma X; Cheng Q; Lin H; Jin X; Zhang Z; Yu W; He S; Kobayashi T; Uehara S; Matsumoto T; Xia W
    J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women.
    Kharroubi A; Saba E; Smoom R; Bader K; Darwish H
    Arch Osteoporos; 2017 Dec; 12(1):13. PubMed ID: 28124221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment.
    Chavassieux P; Chapurlat R; Portero-Muzy N; Roux JP; Garcia P; Brown JP; Libanati C; Boyce RW; Wang A; Grauer A
    J Bone Miner Res; 2019 Sep; 34(9):1597-1608. PubMed ID: 31233639
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C; Woitge HW; Witte K; Lemmer B; Seibel MJ
    J Bone Miner Res; 2004 Aug; 19(8):1221-30. PubMed ID: 15231008
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
    Deane A; Constancio L; Fogelman I; Hampson G
    BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vitamin D supplementation and bone mineral density in early postmenopausal women.
    Cooper L; Clifton-Bligh PB; Nery ML; Figtree G; Twigg S; Hibbert E; Robinson BG
    Am J Clin Nutr; 2003 May; 77(5):1324-9. PubMed ID: 12716689
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
    Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Suzuki T; Nakamura Y; Tanaka M; Kamimura M; Ikegami S; Uchiyama S; Kato H
    Mod Rheumatol; 2018 Mar; 28(2):376-379. PubMed ID: 28397581
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
    Ebina K; Noguchi T; Hirao M; Kaneshiro S; Tsukamoto Y; Yoshikawa H
    J Bone Miner Metab; 2016 May; 34(3):243-50. PubMed ID: 26303222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study.
    Inage K; Orita S; Eguchi Y; Shiga Y; Koda M; Aoki Y; Kotani T; Akazawa T; Furuya T; Nakamura J; Takahashi H; Suzuki-Narita M; Maki S; Hagiwara S; Inoue M; Norimoto M; Kinoshita H; Sato T; Sato M; Enomoto K; Takaoka H; Mizuki N; Hozumi T; Tsuchiya R; Kim G; Otagiri T; Mukaihata T; Hishiya T; Ohtori S
    Yonsei Med J; 2021 Sep; 62(9):829-835. PubMed ID: 34427069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
    Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
    Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis.
    Lewiecki EM; Blicharski T; Goemaere S; Lippuner K; Meisner PD; Miller PD; Miyauchi A; Maddox J; Chen L; Horlait S
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3183-3193. PubMed ID: 29931216
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis.
    Nuti R; Bianchi G; Brandi ML; Caudarella R; D'Erasmo E; Fiore C; Isaia GC; Luisetto G; Muratore M; Oriente P; Ortolani S
    Rheumatol Int; 2006 Mar; 26(5):445-53. PubMed ID: 16283320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.